129 related articles for article (PubMed ID: 18554583)
1. Prevention of nitroglycerin tolerance in vitro by T0156, a selective phosphodiesterase type 5 inhibitor.
Liu CQ; Leung FP; Lee VW; Lau CW; Yao X; Lu L; Huang Y
Eur J Pharmacol; 2008 Aug; 590(1-3):250-4. PubMed ID: 18554583
[TBL] [Abstract][Full Text] [Related]
2. Prostanoid TP receptor-mediated impairment of cyclic AMP-dependent vasorelaxation is reversed by phosphodiesterase inhibitors.
Liu CQ; Wong SL; Leung FP; Tian XY; Lau CW; Lu L; Yao X; Chen ZY; Yao T; Huang Y
Eur J Pharmacol; 2010 Apr; 632(1-3):45-51. PubMed ID: 20096281
[TBL] [Abstract][Full Text] [Related]
3. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
[TBL] [Abstract][Full Text] [Related]
4. Role of endogenous hydrogen peroxide in the development of nitrate tolerance.
Ghatta S; Hemmer RB; Uppala S; O'Rourke ST
Vascul Pharmacol; 2007 Apr; 46(4):247-52. PubMed ID: 17157562
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation.
MacPherson JD; Gillespie TD; Dunkerley HA; Maurice DH; Bennett BM
J Pharmacol Exp Ther; 2006 Apr; 317(1):188-95. PubMed ID: 16330494
[TBL] [Abstract][Full Text] [Related]
6. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
Silver PJ; Dundore RL; Bode DC; de Garavilla L; Buchholz RA; van Aller G; Hamel LT; Bacon E; Singh B; Lesher GY
J Pharmacol Exp Ther; 1994 Dec; 271(3):1143-9. PubMed ID: 7996419
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta.
Korkmaz S; Radovits T; Barnucz E; Neugebauer P; Arif R; Hirschberg K; Loganathan S; Seidel B; Karck M; Szabó G
Eur J Pharmacol; 2009 Aug; 615(1-3):155-62. PubMed ID: 19482016
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor.
Martin W; Furchgott RF; Villani GM; Jothianandan D
J Pharmacol Exp Ther; 1986 May; 237(2):539-47. PubMed ID: 2422344
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta.
Rosenkranz S; Brixius K; Halbach R; Diedrichs H; Schwinger RH
Life Sci; 2006 Feb; 78(10):1103-7. PubMed ID: 16297411
[TBL] [Abstract][Full Text] [Related]
10. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
Kang KK; Yu JY; Yoo M; Kwon JW
Int J Impot Res; 2005; 17(5):409-16. PubMed ID: 15920460
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase.
Liu CQ; Leung FP; Wong SL; Wong WT; Lau CW; Lu L; Yao X; Yao T; Huang Y
Biochem Pharmacol; 2009 Aug; 78(4):374-81. PubMed ID: 19409373
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance.
Kim D; Rybalkin SD; Pi X; Wang Y; Zhang C; Munzel T; Beavo JA; Berk BC; Yan C
Circulation; 2001 Nov; 104(19):2338-43. PubMed ID: 11696475
[TBL] [Abstract][Full Text] [Related]
13. The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model.
Turgut NH; Temiz TK; Bagcivan I; Turgut B; Gulturk S; Karadas B
Eur J Pharmacol; 2008 Jul; 589(1-3):180-7. PubMed ID: 18538317
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor antagonism does not prevent the development of in vivo glyceryl trinitrate tolerance in the rat.
Ratz JD; Fraser AB; Rees-Milton KJ; Adams MA; Bennett BM
J Pharmacol Exp Ther; 2000 Nov; 295(2):578-85. PubMed ID: 11046091
[TBL] [Abstract][Full Text] [Related]
15. Decrease in endogenous CGRP release in nitroglycerin tolerance: role of ALDH-2.
Chen YR; Nie SD; Shan W; Jiang DJ; Shi RZ; Zhou Z; Guo R; Zhang Z; Li YJ
Eur J Pharmacol; 2007 Sep; 571(1):44-50. PubMed ID: 17585900
[TBL] [Abstract][Full Text] [Related]
16. Roles of superoxide, peroxynitrite, and protein kinase C in the development of tolerance to nitroglycerin.
Abou-Mohamed G; Johnson JA; Jin L; El-Remessy AB; Do K; Kaesemeyer WH; Caldwell RB; Caldwell RW
J Pharmacol Exp Ther; 2004 Jan; 308(1):289-99. PubMed ID: 14563789
[TBL] [Abstract][Full Text] [Related]
17. Cross tolerance between nitroglycerin and neural relaxation of the rabbit sphincter of Oddi.
Sári R; Szilvássy Z; Jakab I; Nagy I; Lonovics J
Pharmacol Res; 1998 Jun; 37(6):505-12. PubMed ID: 9695125
[TBL] [Abstract][Full Text] [Related]
18. Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia.
Kang KK; Kim JM; Yu JY; Ahn BO; Yoo M; Kim YC
Int J Urol; 2007 Oct; 14(10):946-51; discussion 951. PubMed ID: 17880297
[TBL] [Abstract][Full Text] [Related]
19. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast.
Pagani ED; VanAller GS; O'Connor B; Silver PJ
Eur J Pharmacol; 1993 Oct; 243(2):141-7. PubMed ID: 8276063
[TBL] [Abstract][Full Text] [Related]
20. Formation of releasable NO stores by S-nitrosoglutathione in arteries exhibiting tolerance to glyceryl-trinitrate.
Sarr M; Lobysheva I; Diallo AS; Stoclet JC; Schini-Kerth VB; Muller B
Eur J Pharmacol; 2005 Apr; 513(1-2):119-23. PubMed ID: 15878716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
